Feb 19, 2009 (Datamonitor via COMTEX) –
— Cordex Pharma, a developer of new cardiovascular medicines, has submitted to the FDA an amended Phase III protocol for ATPace to be reviewed as a special protocol assessment.
According to Cordex, the amendment addresses written comments recently received from the FDA in response to the company’s initial special protocol assessment (SPA) submission to the FDA in November 2008.
Amir Pelleg, Cordex’s Read the rest of this entry »

According to Cordex, the amendment addresses written comments recently received from the FDA in response to the company’s initial special protocol assessment (SPA) submission to the FDA in November 2008.
Amir Pelleg, Cordex’s president and chief scientific officer, said: “We are very pleased with the FDA’s timely response to our initial ATPace SPA submission. We now believe that the written correspondence from the FDA, which clearly outlines all Read the rest of this entry »

Although 50% of BSHSI’s $1.1 billion debt consists of VRDOs, and $350
million is currently held as bank bonds, the health system’s interest
rate and term-out risk is relatively low. The cure period for all
reimbursement agreements is 366 days, and bank rates are capped at the
higher of the bank’s prime rate plus 1% or the Federal funds rate plus
2%. BSHSI’s long term credit rating and its strengthening credit Read the rest of this entry »